JP2022548270A - フリードライヒ運動失調症の治療のための組成物及び方法 - Google Patents

フリードライヒ運動失調症の治療のための組成物及び方法 Download PDF

Info

Publication number
JP2022548270A
JP2022548270A JP2022516687A JP2022516687A JP2022548270A JP 2022548270 A JP2022548270 A JP 2022548270A JP 2022516687 A JP2022516687 A JP 2022516687A JP 2022516687 A JP2022516687 A JP 2022516687A JP 2022548270 A JP2022548270 A JP 2022548270A
Authority
JP
Japan
Prior art keywords
fxn
nucleic acid
human
utr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548270A5 (https=
Inventor
ダーリン ファルク，
エドガルド ロドリゲス，
マドゥリマ サハ，
Original Assignee
ラセルタ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラセルタ セラピューティクス， インコーポレイテッド filed Critical ラセルタ セラピューティクス， インコーポレイテッド
Publication of JP2022548270A publication Critical patent/JP2022548270A/ja
Publication of JP2022548270A5 publication Critical patent/JP2022548270A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022516687A 2019-09-13 2020-09-11 フリードライヒ運動失調症の治療のための組成物及び方法 Pending JP2022548270A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899953P 2019-09-13 2019-09-13
US62/899,953 2019-09-13
PCT/US2020/050551 WO2021050991A1 (en) 2019-09-13 2020-09-11 Compositions and methods for treatment of friedreich's ataxia

Publications (2)

Publication Number Publication Date
JP2022548270A true JP2022548270A (ja) 2022-11-17
JP2022548270A5 JP2022548270A5 (https=) 2023-07-25

Family

ID=74865919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516687A Pending JP2022548270A (ja) 2019-09-13 2020-09-11 フリードライヒ運動失調症の治療のための組成物及び方法

Country Status (6)

Country Link
US (1) US20220211737A1 (https=)
EP (1) EP4028027A4 (https=)
JP (1) JP2022548270A (https=)
AU (1) AU2020346914A1 (https=)
CA (1) CA3151073A1 (https=)
WO (1) WO2021050991A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4426845A4 (en) * 2021-11-01 2025-10-01 Univ Florida AAV-MEDIATED THERAPIES FOR VISION LOSS ASSOCIATED WITH FRIEDREICH ATAXIA
JP2025537125A (ja) * 2022-11-01 2025-11-14 プリベイル・セラピューティクス・インコーポレイテッド フリードライヒ運動失調症の治療のための組成物及び方法
WO2025157942A2 (en) * 2024-01-23 2025-07-31 Icm (Institut Du Cerveau Et De La Moelle Épinière) Encapsulated engineered cells for treating a disease or condition affecting the nervous system

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115503A1 (en) * 2015-01-16 2016-07-21 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
WO2016172659A1 (en) * 2015-04-24 2016-10-27 University Of Florida Research Foundation, Inc. Aav vector for treatment of friedreich's ataxia
US20180140721A1 (en) * 2016-11-09 2018-05-24 Intrexon Corporation Frataxin expression constructs
JP2018531609A (ja) * 2015-11-05 2018-11-01 バンブー セラペウティクス インク 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター
WO2019076973A1 (en) * 2017-10-17 2019-04-25 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol VECTORS FOR THE TREATMENT OF FRIEDREICH ATAXIA

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018004755A (es) * 2015-10-29 2018-12-19 Voyager Therapeutics Inc Entrega de polinucleotidos dirigidos al sistema nervioso central.
EP3641834B1 (en) * 2017-06-19 2023-10-04 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia
WO2019000093A1 (en) * 2017-06-29 2019-01-03 UNIVERSITé LAVAL PLATINUM TALE AND USE THEREOF TO INCREASE THE EXPRESSION OF FRATAXIN

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115503A1 (en) * 2015-01-16 2016-07-21 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
WO2016172659A1 (en) * 2015-04-24 2016-10-27 University Of Florida Research Foundation, Inc. Aav vector for treatment of friedreich's ataxia
JP2018531609A (ja) * 2015-11-05 2018-11-01 バンブー セラペウティクス インク 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター
US20180140721A1 (en) * 2016-11-09 2018-05-24 Intrexon Corporation Frataxin expression constructs
WO2019076973A1 (en) * 2017-10-17 2019-04-25 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol VECTORS FOR THE TREATMENT OF FRIEDREICH ATAXIA

Also Published As

Publication number Publication date
EP4028027A1 (en) 2022-07-20
AU2020346914A1 (en) 2022-04-21
CA3151073A1 (en) 2021-03-18
WO2021050991A1 (en) 2021-03-18
US20220211737A1 (en) 2022-07-07
EP4028027A4 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US20240226203A9 (en) Compositions and methods of treating huntington's disease
Bevan et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders
EP3364970B1 (en) Gene therapy for use in treating lysosomal storage disease
Samaranch et al. Adeno-associated viral vector serotype 9–based gene therapy for Niemann-Pick disease type A
Hadaczek et al. Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response
US20260049335A1 (en) Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
ES3061210T3 (en) Gene therapy for ocular disorders
US12357663B2 (en) Intrathecal delivery of recombinant adeno-associated virus encoding methyl-CpG binding protein 2
US20220275367A1 (en) Compositions and methods for treating huntington's disease
US20230227802A1 (en) Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
KR20180027619A (ko) 신경변성 질환에 대한 유전자 요법
JP2019536465A (ja) ＩＬ−１Ｒａ ｃＤＮＡ
JP2022548270A (ja) フリードライヒ運動失調症の治療のための組成物及び方法
JP2023535121A (ja) 操作されたパーキン及びその使用
JP7253274B2 (ja) Ａａｖ適合性ラミニン－リンカー重合タンパク質
US20230210941A1 (en) Compositions useful in treatment of krabbe disease
IL322184A (en) Compositions and methods for treating neurological disorders associated with glucosylceramide beta 1 deficiency
Bevan et al. This chapter has been published in the peer-reviewed journal Molecular Therapy. This work is the result of collaboration with the authors listed below. I helped design and perform experiments and write the manuscript, especially all experiments using nonhuman primates.
Bradbury Immunomodulatory Effects of Intracranial Gene Therapy in Feline Sandhoff Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251104